Home | Free 30-Day Trial | Tutorial | Help
Medical Disability Advisor  >  Arthritis Rheumatoid  >  Treatment

Arthritis, Rheumatoid


Related Terms


  • Chronic Inflammatory Arthritis
  • Proliferative Arthritis
  • RA
  • Systemic Arthritis

Specialists


  • Emergency Medicine Physician
  • Infectious Disease Internist
  • Internal Medicine Internist
  • Occupational Therapist
  • Orthopedic (Orthopaedic) Surgeon
  • Physiatrist
  • Physical Therapist
  • Rheumatologist

Sign-in as a subscriber or take a free trial to see the renowned Reed Group physiological recovery durations in place of this advertising.

Factors Influencing Duration


Although some individuals have mild symptoms that resolve, most people experience progressive disease over the course of their lifetime. The individual's age, the rate of disease progression, the severity of the disease, which joints and how many joints are involved, organ system involvement, the response to treatment, and the pattern of remissions and exacerbations all affect the length of disability.

New onset cases with today's disease modifying treatment will usually be able to stay at work, while cases with onsets greater than 10 years ago may have enough destructive arthritis to be permanently unable to do heavy work.

Duration Trends from Reference Data


DURATION TRENDS
 ICD-9-CM: 714.0  
CasesMeanMinMaxNo Lost TimeOver 6 Months
9178304340.5%13.3%
 
  
 
Percentile:5th25thMedian75th95th
Days:82963112199
 
  
 

Differences may exist between the duration tables and the reference graphs. Duration tables provide expected recovery periods based on the type of work performed by the individual. The reference graphs reflect the actual experience of many individuals across the spectrum of physical conditions, in a variety of industries, and with varying levels of case management. Selected graphs combine multiple codes based on similar means and medians.

Medical Codes


ICD-9-CM:
710.2 - Diffuse Diseases of Connective Tissue, Sicca Syndrome; Sjögrens Disease; Keratoconjunctivitis Sicca (Sicca Syndrome)
714 - Rheumatoid Arthritis and Other Inflammatory Polyarthropathies
714.0 - Rheumatoid Arthritis; Arthritis or Polyarthritis: Atrophic, Rheumatic (Chronic)
714.1 - Feltys Syndrome; Rheumatoid Arthritis with Splenoadenomegaly and Leukopenia
714.2 - Other Rheumatoid Arthritis with Visceral or Systemic Involvement; Rheumatoid Carditis
714.8 - Other Specified Inflammatory Polyarthropathies
714.81 - Rheumatoid Lung; Caplans Syndrome; Diffuse Interstitial Rheumatoid Disease of Lung; Fibrosing Alveolitis, Rheumatoid
714.89 - Other Specified Inflammatory Polyarthropathies, Other
714.9 - Unspecified Inflammatory Polyarthropathy

Treatment


Treatment for RA has changed dramatically and newer medications can help prevent joint damage. The goal of RA treatment is to control synovitis and thus prevent joint damage and disability. Optimal management involves a combination of nonpharmacological therapy (i.e., rest, exercise, stress reduction, diet modification, psychotherapy or counseling, massage, and physical therapy) and drug therapy. Although regular rest is recommended and complete bed rest may be indicated during flare-ups (disease exacerbations), individuals with RA respond favorably to gentle exercise such as walking, yoga and stretching exercises.

Drugs are prescribed for pain management (analgesia), to control inflammation, and to suppress the immune response. Nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), which include cyclooxygenase-2 (COX-2) inhibitors (celecoxib), provide important symptomatic relief of pain and inflammation, but do not alter the long-term course of the disease.

There has been a growing emphasis on early diagnosis and intensive treatment since joint damage occurs early in the course of the disease. Disease-modifying antirheumatic drugs (DMARDs) are a diverse group of therapeutic agents that can slow disease progression. Some examples of DMARDs are methotrexate, sulfasalazine, and hydroxychloroquine. Biological agents are man-made analogs of naturally occurring molecules that interfere with joint inflammation and destruction. Leflunomide inhibits pyrimidine synthesis. Tumor necrosis factor (TNF) antagonists (etanercept, infliximab, adalimumab) inhibit TNF, a mediator of joint inflammation. Another class of biological agents (abatacept, rituximab) act by inhibiting the interleukin-1 receptor. Combinations of DMARDs and biological agents are used to delay radiologic progression of disease and achieve remission. Medications used to treat RA may have serious side effects so regular monitoring is necessary.

Injections of corticosteroids into affected joints or short-term use of oral corticosteroids may provide relief for acute flare-ups, but are seldom used on a continuing basis because of significant long-term toxicity

Splinting of inflamed joints is sometimes employed to decrease synovitis, prevent deformity, and improve limb function. Surgical treatment, such as to remove synovial tissue (synovectomy), repair joints (arthroplasty), or replace joints, is reserved for the most severe cases in which joints have been completely destroyed and mobility is severely compromised.

Source: Medical Disability Advisor






Feedback
Send us comments, suggestions, corrections, or anything you would like us to hear. If you are not logged in, you must include your email address, in order for us to respond. We cannot, unfortunately, respond to every comment. If you are seeking medical advice, please contact your physician. Thank you!
Send this comment to:
Sales Customer Support Content Development
 
This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is published with the understanding that the author, editors, and publisher are not engaged in rendering medical, legal, accounting or other professional service. If medical, legal, or other expert assistance is required, the service of a competent professional should be sought. We are unable to respond to requests for advice. Any Sales inquiries should include an email address or other means of communication.